Showing 1241-1250 of 3024 results for "".
- Tolebrutinib vs Teriflunomide Treatment for Individuals with Relapsing MShttps://practicalneurology.com/news/study-compares-tolebrutinib-vs-teriflunomide-as-treatment-for-individuals-with-relapsing-ms/2473966/Analysis of results from two clinical trials presented at the American Academy of Neurology (AAN) 2025 Annual Meeting revealed no significant difference in the adjusted annualized relapse rate (ARR) in individuals with relapsing multiple sclerosis (RMS) treated with either tolebrutinib (Sanofi; B
- Antidepressants Safe in Those Taking Ozanimod for Relapsing MShttps://practicalneurology.com/news/antidepressants-safe-in-those-taking-ozanimod-for-relapsing-ms/2470123/Data presented at the Americas Committee for Treatment & Research in Multiple Sclerosis (ACTRIMS) Forum 2023 suggest that concurrent administration of ozanimod (Zeposia; Bristol Myers Squibb, New York, NY) with selectiv
- Standard Health Outcomes Recommended for Relapsing-Remitting MShttps://practicalneurology.com/news/standard-health-outcomes-recommended-for-relapsing-remitting-ms/2470122/A multidisciplinary scientific committee reported on their initiative to define a set of standard health outcomes for relapsing-remitting multiple sclerosis (R
- Ozanimod Comparable to Diroximel Fumarate for Relapsing-Remitting MShttps://practicalneurology.com/news/ozanimod-comparable-to-diroximel-fumarate-for-relapsing-remitting-ms/2470121/According to results from a matching-adjusted indirect comparison study, ozanimod (Zeposia; Bristol Myers Squibb, New York, NY) had
- Biosimilar Found Equivalent to Natalizumab for Relapsing-Remitting MShttps://practicalneurology.com/news/biosimilar-found-equivalent-to-natalizumab-for-relapsing-remitting-ms/2470108/
- Masitinib Reduced Disability Progression in People With Progressive MShttps://practicalneurology.com/news/masitinib-reduced-disability-progression-in-people-with-progressive-ms/2469840/As published in Neurology Neuroimmunology & Neuroinflammation, results from a phase 3 trial (NCT01433497) of masitinib (AB Science; Paris, Franc
- Positive Phase 2 Results for Evobrutinib Treatment of MS and Initiation of Phase 3 Trialshttps://practicalneurology.com/news/positive-phase-2-results-for-evobrutinib-treatment-of-ms-and-initiation-of-phase-3-trials/2469014/At the European Committee on Research and Treatment in Multiple Sclerosis (ECTRIMS) Congress in Stockholm, Sweden September 11-13, 2019, data from a phase 2 trial (NCT02975349) of evobrutinib (EMD Serono, Rockland, MD) for treatment of
- Evidence of Remyelination Seen in People with MS Receiving Combination Therapyhttps://practicalneurology.com/news/evidence-of-remyelination-seen-in-people-with-ms-receiving-combination-therapy/2483873/Combined treatment with metformin, a biguanide used to treat diabetes mellitus type 2, and clemastine, a antihistamine, may promote myelin repair in people with multiple sclerosis, according to results of the phase 2 CCMR-Two clinical trial (NCT05131828) presented at the 41st Congress
- FDA Delays Decision on Tolebrutinib for Non-Relapsing Secondary Progressive MShttps://practicalneurology.com/news/fda-delays-decision-on-tolebrutinib-for-non-relapsing-secondary-progressive-ms/2483482/The Food and Drug Administration (FDA) has extended its review period for tolebrutinib (Sanofi, Bridgewater, NJ), moving the Prescription Drug User Fee Act (PDUFA) decision date from September 28 to December 28, 2025. Tolebrutinib is an oral, brain-penetrant Bruton's tyrosine kinase (BTK) inhibit
- Guidelines for Use of Stem Cell Transplantation for Refractory MS and NMOSD Publishedhttps://practicalneurology.com/news/guidelines-for-use-of-stem-cells-for-refractory-ms-and-nmosd-published/2474472/A new consensus statement from the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and the European Society for Blood and Marrow Transplantation (EBMT) provides updated guidance on the use of autologous hematopoietic stem cell transplantation (AHSCT) in individuals d